Attached files
| file | filename |
|---|---|
| EX-23.1 - EX-23.1 - NRX Pharmaceuticals, Inc. | d175615dex231.htm |
| EX-5.1 - EX-5.1 - NRX Pharmaceuticals, Inc. | d175615dex51.htm |
| S-1/A - S-1/A - NRX Pharmaceuticals, Inc. | d175615ds1a.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated May 11, 2021, with respect to the consolidated financial statements of NeuroRx, Inc., included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Short Hills, New Jersey
July 6, 2021